Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Locally Advanced or Metastatic Cancer in Response After 6 Months of Standard IO

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05078047
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:43.571761+00:00
Published At
2025-06-05T00:00:00+00:00
Record Updated At
2025-06-05
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Lung Cancer Metastatic", "Renal Cell Carcinoma", "Head and Neck Cancer", "Triple Negative Breast Cancer", "Merkel Cell Carcinoma", "Hepatocellular Carcinoma", "Melanoma", "Urothelial Carcinoma", "Colorectal Carcinoma With Microsatellite Instability", "Esophageal Squamous Cell Carcinoma", "Endometrial Carcinoma", "Cervical Cancer", "Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinoma", "Basal Cell Carcinoma", "Squamous Skin Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-06-05"
protocolSection.identificationModule.nctId
"NCT05078047"
protocolSection.identificationModule.officialTitle
"Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Locally Advanced or Metastatic Cancer in Response After 6 Months of Standard IO"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Lung Cancer Metastatic (protocolSection.conditionsModule.conditions)
  • Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Head and Neck Cancer (protocolSection.conditionsModule.conditions)
  • Triple Negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Merkel Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • Melanoma (protocolSection.conditionsModule.conditions)
  • Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Colorectal Carcinoma With Microsatellite Instability (protocolSection.conditionsModule.conditions)
  • Esophageal Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Carcinoma (protocolSection.conditionsModule.conditions)
  • Cervical Cancer (protocolSection.conditionsModule.conditions)
  • Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Basal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Squamous Skin Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.